When to Continue Augmentin (Amoxicillin-Clavulanate) as Antibiotic Therapy
Continue amoxicillin-clavulanate for 5-7 days in adults with uncomplicated acute bacterial rhinosinusitis (ABRS), 10-14 days in children with ABRS, and 10 days for acute otitis media in children. The duration depends primarily on the infection type, patient age, and clinical response.
Duration by Indication
Acute Bacterial Rhinosinusitis (ABRS)
- Adults: 5-7 days for uncomplicated cases 1
- Children: 10-14 days 1
- Start treatment as soon as ABRS is clinically diagnosed 1
The IDSA guideline explicitly recommends amoxicillin-clavulanate over amoxicillin alone as first-line empiric therapy for both adults (weak recommendation) and children (strong recommendation) 1. High-dose formulations (2g twice daily in adults or 90 mg/kg/day in children) should be used in specific circumstances 1.
Acute Otitis Media (AOM)
- Children (3 months to 12 years): 10 days 2
- Clinical studies demonstrate 98.4% bacteriological eradication rates with this duration 2
- The ES-600 formulation (90/6.4 mg/kg/day divided every 12 hours) showed 89.1% clinical success at 2-4 days post-therapy 2
Acute Exacerbations of Chronic Bronchitis (AECB)
- Standard duration: 5-7 days is as effective as longer courses
- A 5-day course of high-dose amoxicillin-clavulanate (2,000/125 mg twice daily) achieved 93% clinical success, equivalent to 7-day conventional dosing 3
COPD Exacerbations
- 3 days may suffice if substantial improvement occurs after initial therapy
- Patients showing improvement after 72 hours can safely discontinue treatment at day 3 rather than continuing to day 10 4
- This shorter course showed comparable cure rates (76% vs 80% at 3 weeks) 4
Critical Decision Points for Continuation
Continue the Full Course When:
- Completing prescribed duration is essential even if symptoms improve early 2
- Skipping doses or early discontinuation decreases treatment effectiveness and promotes resistance 2
- The medication must be taken with meals to reduce gastrointestinal upset 2
Consider Discontinuation When:
- Severe diarrhea develops (watery/bloody stools with or without fever) - contact physician immediately 2
- Superinfections occur (Pseudomonas or Candida) - discontinue and institute appropriate therapy 2
- Mononucleosis is diagnosed - ampicillin-class antibiotics cause erythematous rash in these patients 2
Storage and Compliance Factors:
- Suspension must be refrigerated 2
- Improper storage (especially in hot climates) degrades the antibiotic and causes treatment failure 5
- Shake suspension well before each use 2
Special Populations
Pediatric Considerations:
- Safety and efficacy established for children ≥3 months 2
- Longer durations (10-14 days) remain standard for children with ABRS and AOM 1, 2
- Protocol-defined diarrhea occurred in 12.9% of pediatric patients but was generally manageable 2
Pregnancy and Nursing:
- Category B: use only if clearly needed 2
- Excreted in breast milk - exercise caution in nursing mothers 2
Common Pitfalls to Avoid
- Do not routinely add MRSA coverage during initial empiric therapy for ABRS 1
- Do not use in viral infections - this provides no benefit and promotes resistance 2
- Do not extend therapy beyond recommended durations without clear clinical indication
- Monitor for C. difficile - can occur up to 2+ months after last dose 2
- Ensure proper storage - degraded medication from heat exposure causes treatment failure 5
Adjunctive Therapy Recommendations
When continuing amoxicillin-clavulanate for ABRS, consider adding:
- Intranasal saline irrigation (weak recommendation) 1
- Intranasal corticosteroids, especially with allergic rhinitis history (weak recommendation) 1
- Avoid topical/oral decongestants and antihistamines as routine adjuncts 1
The evidence strongly supports shorter courses when clinically appropriate, particularly in adults with uncomplicated infections who demonstrate early clinical improvement. However, the full prescribed course must be completed to prevent resistance development and treatment failure.